Diseases such as cancer and diabetes offer $40bn in business to African pharma
The growing incidence of lifestyle diseases such as cardiovascular disease (CVD)‚ cancer‚ diabetes and respiratory disease‚ in addition to infectious and parasitic illness‚ will present the pharmaceutical industry in Africa with a business opportunity of $40.8bn in 2019‚ according to research by Frost & Sullivan. And the pharmaceuticals market in Africa is expected to represent a business opportunity of $45bn by 2020‚ it added. "An increase in health spending will encourage local manufacture of drugs‚" said Transformational Health research analyst Saravanan Thangaraj. "We expect this increase in local formulation and filling to be protected by regulatory and tariff barriers‚ so international players will be looking for local contract manufacturers and other strategic partnerships." A report‚ titled African Pharmaceuticals Market‚ Forecast to 2020‚ part of Frost & Sullivan’s Life Sciences Growth Partnership Service programme‚ aims to provide insights for big pharmaceutical companies ...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.